

11/13/00  
JC890 U.S. PTO11.15.00  
A

PTO/SB/05 (11-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY  
PATENT APPLICATION  
TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.	0003/00537
First Inventor	Fred J. STEVENS
Title	FIBRIL BLOCKING PEPTIDE...

Express Mail Label No. EL 031465106 US

PTO

JC893 U.S.  
09/12/2000

11/13/00

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)
2.  Applicant claims small entity status.  
See 37 CFR 1.27.
3.  Specification [Total Pages 19]  
(preferred arrangement set forth below)
  - Descriptive title of the invention
  - Cross Reference to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to sequence listing, a table, or a computer program listing appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
4.  Drawing(s) (35 U.S.C. 113) [ Total Sheets 4 ]
5. Oath or Declaration [ Total Pages ]  
 a.  Newly executed (original or copy)  
 b.  Copy from a prior application (37 CFR 1.63 (d))  
 (for continuation/divisional with Box 18 completed)
  - i.  **DELETION OF INVENTOR(S)**  
Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).
6.  Application Data Sheet. See 37 CFR 1.76

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

7.  CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)
8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
  - a.  Computer Readable Form (CRF)
  - b. Specification Sequence Listing on:
    - i.  CD-ROM or CD-R (2 copies); or
    - ii.  paper
  - c.  Statements verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

9.  Assignment Papers (cover sheet & document(s))
10.  37 CFR 3.73(b) Statement  Power of (when there is an assignee)  Attorney
11.  English Translation Document (if applicable)
12.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
13.  Preliminary Amendment
14.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
15.  Certified Copy of Priority Document(s) (if foreign priority is claimed)
16.  Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.
17.  Other: .....

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76:


 Continuation  Divisional  Continuation-in-part (CIP) of prior application No. /

Prior application information: Examiner \_\_\_\_\_ Group Art Unit: \_\_\_\_\_

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

## 19. CORRESPONDENCE ADDRESS

<input type="checkbox"/> Customer Number or Bar Code Label	(Insert Customer No. or Attach bar code label here)			<input type="checkbox"/> or <input type="checkbox"/> Correspondence address below
Name	CHERSKOV & FLAYNIK			
Address	The Civic Opera Building			
	20 N. Wacker Drive			
City	Chicago	State	IL	Zip Code
Country	U.S.A.	Telephone	312-621-1330	Fax 621-0088

Name (Print/Type)	Michael J. Cherskov	Registration No. (Attorney/Agent)	33,664
Signature			Date Nov. 13, 2000

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

**CHERSKOV & FLAYNIK**

LAWYERS

THE CIVIC OPERA BUILDING  
20 NORTH WACKER DRIVE  
CHICAGO, ILLINOIS 60606  
PATENTS@INTERACCESS.COM

JC893 U.S. PTO  
09/712819  
11/13/00

TELEPHONE (312) 621-1330

FACSIMILE (312) 621-0088


**CERTIFICATE OF MAILING BY EXPRESS MAIL**

Express Mail mailing label number EL 031465106 US

I certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated below and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

MICHAEL J. CHERSKOV

(Typed or printed name of person mailing paper or fee)

  
Signature

November 13, 2000

Date of Deposit

November 13, 2000

Assistant Commissioner of  
Patents  
Box Patent Application  
Washington, D.C. 20231

Sir:

We enclose herewith the patent application of Fred J. STEVENS, et al entitled "A FIBRIL-BLOCKING PEPTIDE, A METHOD FOR PREVENTING FIBRIL FORMATION" (Atty Docket Number 0003/00537), including the specification, a set of 20 claims, and 4 sheets of formal drawing. Also enclosed is an Information Disclosure Statement and a Self-Addressed Postcard. This Application is being filed at this time without a Declaration with Power of Attorney, pursuant to 37 C.F.R. §1.53(b). The undersigned asserts that the Applicants are small entities.

There are four inventors in this matter.

- 1.) Fred J. STEVENS, a U.S. Citizen residing at  
548 Beaconsfield Avenue  
Naperville, IL 60565

In Re: STEVENS (Attny Dkt # 0003/00537)  
Patent Application Transmittal Letter  
Page -2-

and

2.) Yair ARGON, a U.S. Citizen residing at  
2404 Braeburn Avenue  
Flossmoor, IL 60422

3.) David P. DAVIS a U.S. Citizen residing at  
5457 S. Cornell Avenue  
Chicago, IL 60615

4.) Rosemarie RAFFEN a U.S. Citizen residing at  
796 Spring  
Elmhurst, IL 60126

Please direct all correspondence to the undersigned at the address indicated in the letterhead above.

Respectfully,

CHERSKOV & FLAYNIK

By   
Michael J. Cherskov  
(Reg. No. 33,664)

encl.: Patent Application;  
Utility Patent Coversheet  
IDS + One Article  
Postcard

A FIBRIL-BLOCKING PEPTIDE, A METHOD  
FOR PREVENTING FIBRIL FORMATION

Fred J. Stevens  
Yair Argon  
David Davis  
Rosemarie Raffen

**CERTIFICATE OF MAILING BY EXPRESS MAIL**Express Mail mailing label number EL 031465106 US

I certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. 1.10 on the date indicated below and is addressed to Assistant Commissioner for Patents, Washington, D.C. 20231

MICHAEL J. CHERSKOV

(Typed or printed name of person mailing paper or fee)

Signature



Date of Deposit

5  
10  
15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100**A FIBRIL-BLOCKING PEPTIDE, A METHOD  
FOR PREVENTING FIBRIL FORMATION****BACKGROUND OF THE INVENTION****1. Field of the Invention**

This invention relates to a fibril-preventing peptide and a method for preventing the formation of fibrils and more particularly, this invention relates to a peptide and a method for preventing the formation of solid protein structures and disease associated therewith.

**2. Background of the Invention**

"Conformational diseases," share a common etiology whereby proteins fold irregularly to produce structural flaws. These flaws result in the proteins unnaturally aggregating and thereafter precipitating as fibrils from their solvents. Such solvents include blood, urine, water, lymph, cerebrospinal fluid, and other physiological fluids. Diseases such as sickle cell anemia, amyloid light chain disease, senile systemic amyloidosis, Alzheimer's, and prion encephalopathies including kuru and "mad cow" disease or BSE, are the result of protein conformation anomalies.

The immunoglobulin light chain (LC) is normally a soluble, secreted protein, but some light

chains aggregate into ordered fibrils with characteristics similar to other amyloid deposits. Among the human immunoglobulin variable domain ( $V_L$ ) sequences known to form amyloid fibers, somatically mutated derivatives of a small number of germline genes are over-represented. One of these is kappa-IV, many of whose derivatives are associated with light chain amyloidosis. The 5 tendency of kappa-IV sequences to form fibrils is inversely correlated with their thermodynamic stability, and while both stabilizing and destabilizing mutations are found in amyloidogenic kappa-IV sequences, only destabilizing mutations promote fibril formation.

The inventors have found that the conformational change required to convert a soluble light chain into a fibrillogenic variant can be caused by single somatic mutations. Importantly, an 10 aggregating light chain can nucleate fibril formation of a soluble light chain when sufficient sequence compatibility exists. This has important implications in the context of ongoing hypermutations, whereby multiple light chain sequences are generated.

15 Fibril deposition and build-up in tissues is the underlying mechanism of a number of diseases for which no drug therapy currently exists. However, research has shown that flufenamic acid inhibits the conformational changes of transthyretin which is associated with amyloid fibril formation. S.A. Peterson et al. *Proc. Natl. Acad. Sci. USA* (Oct. 27, 1998) 95(22): 12956-60.

Once fibril build-up occurs, often the only intervention is surgical whereby the over-ladened tissue has to be modified or else removed.

20 A need exists in the art for a substance and process to stymie the *in vivo* precipitation of protein. The substance and process should incorporate physiologically compatible materials and require no invasive procedures common with more typical treatments of protein deposit diseases.

#### SUMMARY OF THE INVENTION

It is an object of the present invention to provide a treatment modality for conformational disease that overcomes many of the disadvantages of the prior art.

25 It is another object of the present invention to provide a protocol to stymie the development of fibrils. A feature of the invention is the strategic insertion of a peptide molecule in the subunits of deposition-like proteins. An advantage of the invention is that the insertion prevents fibril formation in the first place, and therefore minimizes morphological tissue changes otherwise associated with deposition accumulation.

Yet another object of the present invention is to provide a substance to aid in the treatment of conformational diseases. A feature of the substance is that it contains an amino acid sequence contained in variable domain regions of proteins which aggregate and subsequently precipitate. An advantage of the substance is that its presence in the various domain regions blocks the domain swapping of the protein with similar light chains and therefore blocks or inhibits the protein aggregation which causes protein precipitation.

Briefly, the invention provides a method for minimizing the aggregation tendencies of an amyloid forming protein, the method comprising identifying a first amino acid sequence of the protein that is replaced by a second amino acid sequence during physiological conditions (e.g., *in vivo*); and preventing the replacement by juxtaposing a peptide to the first amino acid sequence.

The invention provides a method for preventing amyloid formation in human kappa-IV light chain variable domain by inserting the peptide Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub> into the domain, wherein the subscript numbers indicate the residue location on the domain.

The invention provides a peptide for insertion in an intact human kappa-IV light chain variable domain, the peptide comprising the following amino acid sequence:

Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub>

Also provided is a method for preventing fibril assembly, the method comprising identifying a region of a first aggregating protein moiety that normally interacts with a second protein moiety to form the assembly; and juxtaposing a binding protein to the first moiety.

#### BRIEF DESCRIPTION OF THE DRAWING

These and other objects and advantages of the present invention can be better understood from the accompanying drawings whereby:

FIG. 1 is a computer-generated diagram of a hypothetical "Domain Swap" involved in an early step of fibril formation by antibody light chain variable domains;

FIG. 2A depicts a region of a variable light chain from which anti-fibril-forming peptides are derived, in accordance with features of the present invention;

FIG. 2B depicts heptameric residues and their ability to stymie fibril formation, in accordance with features of the present invention;

FIGS. 3A-3F graphically depicts data showing inhibition of fibrillogenesis by binding protein

in accordance with features of the present invention; and

FIG. 4 depicts a schematic diagram of a method for aggregation inhibition *in vivo*, in accordance with features of the present invention

#### DETAILED DESCRIPTION OF THE INVENTION

Generally, the invented method involves identifying submotifs in primary structures that are critical in fibril formation, and then inserting a small biological-molecule inhibitor that stabilizes the normal conformation of a protein. The biological molecule (e.g. a peptide antagonist) functions by blocking the site involved in the interchange of domain segments. A myriad of primary structures are suitable, including but not limited to, unnatural amino acids, peptides, which may be modified to change solubility characteristics, the use of D-amino acids versus L-amino acids, and substances not readily metabolized by the body. For the sake of illustration, subunits of human proteins are utilized herein as the amyloid inhibiting agents.

A thorough discussion of stymying amyloid formation via the invented method is found in D.P. Davis, et al., *Immunity* 13, 433-442 (2000), and incorporated herein by reference.

The inventors utilized an ensemble of kappa-IV somatic mutants as an experimental system to dissect how individual mutations promote the formation of amyloid fiber by light chains and then devised ways to inhibit this reaction.

As described in more detail infra, the inventors demonstrate that *in vitro* fibril formation by light chain variable domains ( $V_L$ ) is blocked by selected peptide insertion and binding protein (BiP) insertion. (BiP is the endoplasmic reticulum chaperone involved in directing normal folding of  $V_L$ .) It was also found that fibril formation is inhibited by a peptide derived from a portion of the  $V_L$  involved in BiP binding.

The inventors discovered that light chains form fibrils through a folding intermediate involved in inter-protein loop swapping. The exposure of the mobile loop, due to a conformational anomaly, may mediate "loop swapping" with other monomers, nucleating fibril formation. Experimental data show that fibril formation is a nucleation-mediated reaction, where the formation of the nuclei is rate-limiting, presumably due to the unfavorable conformational change required in the aggregating unit (such as a  $V_L$  dimer).

A linear peptide is provided herein which blocks such swapping (and therefor the

aggregating) of antibody light chain variable domains. The peptide corresponds to a fragment of intact protein which typically aggregates with another domain to create a dimer. Specifically, the inventors have identified a peptide having a sequence similar to positions 71 through 77 of the human kappa-4 light chain variable domain. The functional sequence is as follows:

Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub>

wherein the subscript numbers are the residue location points in the domain.

The above peptide, when inserted into the core of the aggregating-prone variable domain, provides major anchorage for a hairpin turn spanning residues from position 60 through 83 in the protein. The inventors have found that without an intact anchoring or attachment-point of the hairpin to the core domain, the hairpin detaches itself from the core domain and attaches itself to another domain. Likewise, the cavity remaining in the core domain would be filled by a detached hairpin from another core protein. It is this "domain swap" between core protein domains which results in the formation of highly stable fibrillar assemblies.

Mutations which compromise a highly conservative ionic interaction between residues at positions 61 and 82 are highly correlated with amyloidosis, possibly by compromising the interaction between the hairpin and the domain core. If this interaction is stymied, the hairpin turn readily diffuses away from the core of the domain. This provides an opportunity for the extruded portion (component A) of the protein to insert itself into the corresponding portion of a second molecule (component B). Likewise, the cavity formed in A could be filled by the extruded portion of component B, resulting in an AB dimer in which the polypeptide chains are intermingled. Such intermingling of domains A and B is schematically illustrated in FIG. 1. Further, because the peptide is identical in composition to a portion of the light chain variable domain that is critical for stable packing of the molecule, the observation suggests that it may be possible to generalize this strategy of structural mimicry to develop other peptides that may serve as antagonists (inhibitors) of other conformational disease processes.

The mechanism outlined above also applies to other amyloidogenic proteins that share with variable domains a structural motif known as a "greek key." This motif is characterized by a so-called beta sheet sandwich in which one or more of the hairpin turn structures are found. Amyloid forming proteins such as antibody constant domains, transthyretin, and beta-2-microglobulin are all

members of the aforementioned motif and it may be appropriate to collectively describe this class of amyloid forming proteins as constituting the "greek key amyloidoses." Additionally, serpins (serine protease inhibitors) while not formally greek key proteins, are amyloid forming proteins known to be capable of domain exchange. It is possible that peptides which mimic appropriate portions of the internal structure of any of these proteins may be effective in inhibiting fibril formation. Although the composition of therapeutic peptides are likely to be disease-specific, the approach to developing the therapeutic agents should be common to all "greek key amyloidoses."

5

10

For the sake of this disclosure greek key fold proteins include, but are not limited to, and antibody constant domains, transthyretin, beta-2-microglobulin, serine protease inhibitors, and crystalline.

15

Further, the inventors used an agitation-based in vitro assay to assemble fibrils from two kappa-IV recombinant V<sub>L</sub>, LEN and SMA. LEN was derived as a Bence Jones protein and is a soluble, stable protein, differing from the germline kappa-IV by only one somatic mutation. (Fig. 1a in Inhibition paper). In contrast, SMA formed thioflavin T-binding, Congo red-positive fibrils even without GuHCl.

20

25

#### Heptameric Peptide Inhibition Detail

The inventors found that certain peptides stymie fibril formation otherwise seen in some mutated light chains. As noted in FIGS. 2A-2C, certain heptameric peptides derived from the VL sequence inhibit SMA fibrillogenesis. Each of the peptides emulates a straight span of one beta strand between two turns on the domain involved in fibril formation. The effectiveness of each peptide is indicated in FIG. 2B. Regions of the sequence which provide fibril inhibitors are indicated by black bars, with a prominent region being from residue position 69 to 79. Regions of the sequence not providing effective fibril-blocking peptides are indicated in white bars, and include the region spanning residue number 1 through 7.

FIG. 2C compares the dose dependent inhibition of a fibril blocking peptide FTLTISS and an ineffective fibril blocker TRIFSKL. Fibril formation was measured over time at each peptide concentration. The extent of SMA fibril formation at 45 hours in the presence of various concentration so fthe peptides is plotted relative to that of SMA alone at 45 hours. This time point

was chosen because it was the time required for half-maximal fibril formation with no inhibitor present.

Binding Protein  
Inhibition Detail

In the cellular environment, the endoplasmic reticulum (ER) chaperone BiP is important for regulating the folding of the  $V_L$  domain and putative BiP binding sites on the  $V_L$  were recently mapped. BiP, which stands for binding protein, can itself be bound to a target protein to stymie fibril formation. Chaperones are proteins that mediate correct assembly by causing a target protein to acquire one possible conformation instead of others. Chaperones influence the folding process by directing it toward productive assembly of the correct conformation rather than unproductive alternatives. This process is involved in initial acquisition of the correct conformation. Stable interactions form between parts of the protein that do not interact in the correct conformation when a protein is denatured. When a protein transiently mis-folds as it is initially synthesized, the protein is recognized by chaperones in the same way as comprising incorrect folds. This process is involved in recognizing a protein that has been denatured, and either assisting renaturation or leading to its removal by degradation.

As illustrated in FIG. 3, inclusion of BiP in the *in vitro* seeded SMA aggregation reaction dramatically inhibited fibril assembly and increased the  $V_L$  fraction that remained soluble. BiP's effect was specific, since proteins like lysozome, albumin and ferritin did not significantly decrease fibril formation (See FIG. 3C). BiP captures the mobile loop bearing the alternate hydrophobic side-chains, inhibiting the ability to add aggregating units to the polymer, as well as possibly 'capping' the nuclei of polymerization. The free 69-77 peptide can act as a competitive inhibitor by occupying a crevice vacated by that segment during partial domain unfolding.

In the BiP reactions, SMA fibril formation was assayed in the range of 1 to 1000 moles SMA per mole of fibril antagonist.

FIG. 3A depicts a dose-dependent inhibition of SMA fibril formation by recombinant BiP. For example, at 30 SMA:1 BiP (diamonds), inhibition was very evident at less than 10 percent of the original fluorescence units. At a 100:1 stoichiometric ratio (circles), inhibition was still noted with 75 percent lower fluorescence recorded at early time points. At a 300:1 stoichiometric ratio, 100

percent fluorescence was recorded (triangles) without inhibition.

Another ER chaperone, GRP94, did not inhibit fibril formation as noted in FIG. 3C, with 100 percent maximal fluorescence observed. However, heat shock protein (hsp)70, a family member of BiP, did inhibit fibril formation. Additionally, BiP prevented the ordered aggregation at vastly sub-stoichiometric ratios: as little as 1 mole per 100 moles of SMA exhibited 50% inhibition at 75 hours after mixing. The major effect of BiP was to increase the lag time of aggregation, rather than to reduce the final extent of aggregation. Addition of BiP to preformed fibrils did not reverse the aggregation. These data suggest that BiP is an inhibitor of the formation of a nucleation intermediate, presumably the rate-limiting part of the aggregation reaction, much like in A $\beta$  or prion aggregation.

The ability of BiP to inhibit SMA fibril assembly was dependent on its peptide binding capacity. Cycles of binding and release are not essential for BiP inhibition of fibril formation. As can be noted in FIG. 3D, wild type BiP without added nucleotide (black bars) or in the presence of ADP (striped bars) inhibited fibril formation equivalently, while addition of ATP (stippled bars) decreased the efficiency of BiP inhibiting fibrillogenesis. Further, a BiP mutant with a substitution in the nucleotide binding site (T19G) inhibited fibril assembly as effectively as wild type BiP. This mutant is locked in the high affinity binding state, since upon nucleotide binding T19G BiP cannot transmit a conformational change in the peptide binding domain and release the substrate.

As depicted in FIG. 3E, prebinding BiP with the peptide FYQLALT, which is a high affinity pan-hsp70 substrate not derived from light chain, blocked the chaperone's ability to suppress fibril assembly. The filled diamonds in the graph depict good fibril depression if BiP is not incubated in the presence of the peptide prior to aggregation reaction. Conversely, when BiP is incubated in the presence of the peptide prior to addition to standard aggregation reaction, fibril prevention ability decreases. As in FIG. 3C, Lysozyme showed no appreciable fibril blocking ability, either alone (filled squares) or when pretreated with the peptide (open squares).

Furthermore, BiP progressively converts to its monomeric form upon incubation with SMA, as observed for BiP-peptide interactions. BiP binds to the aggregating V<sub>L</sub> unit and/or prevents formation of the nucleation intermediate. Since BiP is present in the ER of plasma cells at a vast molar excess compared to light chain, its activity may explain why light chain amyloids are commonly found as extracellular aggregates rather than intra cellularly.

Peptides derived from the VL sequence, including known BiP-binding peptides, were tested for their ability to prevent SMA fibril formation. Eighteen synthetic peptides spanning most of the VL sequence were tested. Of them, PKLLIYWA (44-51) exhibited partial inhibition and the overlapping peptides TDFTLTI (amino acids 69-75) and FTLTISS (71-77) markedly inhibited the aggregation. The peptide FTLKISR, a 71-77 sequence common to a number of VL germline genes inhibited as well as FTLTISS and also inhibited fibril assembly of the peptide  $\lambda$ 6 VL protein. Specific structural features of the sequence 71-77 are important for inhibiting aggregation. Peptides in which Phe71 or Ile75 were replaced by Leu were effective inhibitors. However, a peptide with the same amino acids as in the native sequence but in a scrambled order did not inhibit, nor did any of the peptides with Phe71, Leu73 or Ile75 in FTLKISR replaced by Ala. Placement of a Pro in a middle of the peptide also abolished its inhibitory capacity, suggesting that the extended conformation of the peptide is essential.

The inventors have found that the same features of the peptide required for inhibiting aggregation are also necessary for this peptide's binding to BiP. The ability of both BiP and its target VL peptide to inhibit aggregation therefore suggests that under aggregation-promoting conditions, the loop containing the TDFTLTISS peptide in SMA is not anchored properly in the body of the V domain. The peptide inhibits fibril formation through interactions between its hydrophobic patch on partially unfolded SMA that mimics the BiP binding site.

The readiness with which SMA adopts fibrillogenic conformation as compared to LEN must be due to the minimal sequence differences between the two.

In addition to suggesting a molecular mechanism for light chain amyloidosis, the inventors' results also imply that many somatic mutants of immunoglobulin are involved in such aggregation. Only one (or a few) destabilizing mutation(s) is required to convert a soluble protein to an aggregate prone variation. Further, even if such a mutant does not aggregate spontaneously, it may be induced to form fibrils by the presence of another aggregating light chain, a potentially common *in vivo* event.

Identification of these specific structural features should facilitate future development of rational strategies for drug discovery across the spectrum of amyloid disease.

In Vivo AggregationInhibition Detail

The complete LC of SMA or LEN have been expressed in COS cells. The inventors found that amyloidogenic protein can aggregate intracellularly. Unlike LEN, SMA is slow to fold and is readily recognized as an unstable protein; it is dislocated into the cytosol, where it either aggregates into inclusion bodies or is degraded by proteasomes. The chaperone Hsp70 interacts with SMA in the cytosol and plays an important role in its fate. Over-expression of Hsp70 improves the solubility of SMA and decreases its aggregation.

The inventors found that the same molecular surface required for fibril formation *in vitro* is important for aggregation *in vivo*. The same Hsp70-binding peptide which we showed to inhibit fibril assembly *in vitro* prevents aggregation of SMA in cells. This ability to modulate the degree of intracellular LC aggregation with chaperones and peptides suggests that rationally designed peptides may provide effective treatment modalities for a variety of amyloidoses.

Plasmids: For the purpose of expressing SMA and LEN *in vivo*, expression plasmids were constructed that direct the synthesis of complete kappa chains, containing either of these two variable region sequences followed by the constant region of human C $\kappa$ , as disclosed by Hieter et al., *Cell*, 22, 197-207, and incorporated herein by reference. Pulse-chase analysis of COS cells transiently expressing these  $\kappa$  chains revealed that LEN was secreted as a wild type LC, but that SMA was not secreted.

Constructs directing expression of the complete SMA and LEN LC, wild type BiP and T19G BiP are disclosed in the Davis paper, earlier incorporated by reference herein. An Hsp70 expression plasmid was constructed by PCR amplification of the inducible gene from the pETWThsp70 vector (Abravaya et al., 1992). Amplified material was inserted into the vector pcDNA3.1 (Invitrogen, Carlsbad, CA).

COS-1 cells were transiently transfected with FuGENE 6 transfection reagent (Roche Molecular Biochemicals, Indianapolis, IN) according to manufacturer's instructions and analyzed two days later. Overnight incubations with various concentrations of ALLN (Sigma Chemical Co., St. Louis, MO), 10  $\mu$ M lactacystin (Calbiochem, La Jolla, CA), 10  $\mu$ g/ml nocodazole (Sigma), or various concentrations of peptides were begun the day following transfection.

Culture, metabolic labeling, lysis and immunoprecipitation of COS-1 cells were performed

as described in Dul et al. *Immunol.* **149**, 1927-1933 (1992), and incorporated herein by reference. The following antibodies were used in immunoprecipitations: rabbit anti-human kappa antibody (Bethyl Labs, Montgomery, TX); goat anti-human kappa (Caltag, Burlingame, CA); mouse anti-ubiquitin (StressGen, Victoria, BC, Canada).

5 Cells were transfected in 6-well dishes and lysed in the wells with 200  $\mu$ l each of the following buffer: 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 5 mM KCl, 5 mM MgCl<sub>2</sub>, 0.5% Triton X-100, 0.5% deoxycholate, and 20 mM NEM, supplemented with protease inhibitors (1  $\mu$ g/ml each of leupeptin and pepstatin A; 10  $\mu$ g/ml each of TLCK, TPCK and soybean trypsin inhibitor). The lysates were passed through a 25 gauge needle 10 times on ice. Insoluble material was recovered by 10 centrifugation at 16,000 g for 15 min. Pellets were solubilized in 50  $\mu$ l 60 mM Tris-HCl, pH 6.8, 5% SDS, 10% glycerol with 1 min of sonication in a cuphold sonicator, followed by 10 min of boiling. Samples were separated on 11% SDS-PAGE gels and transferred to nitrocellulose. Membranes were 15 incubated with goat anti-human kappa (BioSource, Camarillo, CA) and HRP-conjugated donkey anti-goat IgG (Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-VSV G (J. Burkhardt, Univ. of Chicago) and HRP-conjugated goat anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA); mouse anti-raf (Transduction Labs, Lexington, KY) and HRP-conjugated goat anti-mouse IgG (Jackson). Bound antibodies were detected with SuperSignal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL). Blots were quantitated using scanning densitometry and NIH Image 1.6 software.

20 A peptide was synthesized that fused an HIV TAT sequence (YGRKKRRQRRR) with the V<sub>L</sub> derived sequence which the inventors have shown inhibit fiber formation *in vitro*, discussed supra. To ensure adequate flexibility and solubility, additional V<sub>L</sub> sequence was added on both sides of the active 7-mer, generating the following sequence for the TAT-TISS peptide: NH<sub>2</sub>-YGRKKRRQRRSGSGTDFLTISSSLQAED-OH. A control peptide was synthesized (TAT-PASS) 25 in which the critical hydrophobic residues were substituted with alanines and the extended structure of the peptide destroyed by the addition of a proline (NH<sub>2</sub>-YGRKKRRQRRSGSGTAPASSLQAED-OH). Cells were treated with either peptide 24 h after transfection and incubated overnight in the presence of the indicated concentrations of ALLN. Cells were then harvested for western blotting or immunofluorescence as described above.

As noted supra, recombinant Hsp70 blocked fibril formation by recombinant variable domains *in vitro*. BiP, the ER homologue of Hsp70, also prevented *in vitro* fibril formation, but was less efficient than Hsp70.

The inventors have found that BiP suppressed aggregation *in vivo*. In particular, a mutant BiP that is unable to release substrate (T19G BiP), caused a larger pool of SMA to be retained within the ER and decreased the frequency of aggresome formation. The inventors also found that co-expression of Hsp70 with SMA decreases the frequency of aggresome formation. Without ALLN treatment 30% of the COS cells contained aggresomes as assayed by immunofluorescence. Addition of ALLN increased the proportion to 75%, but co-expression of Hsp70 dramatically decreased the frequency of aggresomes to 12% whether or not ALLN was present.

To further investigate the effects of Hsp70 and BiP on the aggregation of SMA *in vivo*, the inventors used a biochemical assay. The inventors found that forced interaction with these chaperones improves the fate of SMA. When BiP or T19G BiP were co-expressed with SMA, a modest effect on the pool size of soluble LC was observed, as compared to cells transfected with SMA alone. This effect was variable in the absence of ALLN, but consistently observed in the presence of ALLN. Co-expression of either of these chaperones had no effect on the size of the insoluble SMA pool.

The inventors further found that over-expression of cytosolic Hsp70, had a dramatic effect on SMA aggregation, both quantitatively and qualitatively. The yield of insoluble SMA was reduced 3- to 8-fold, while that of soluble SMA was proportionately increased. Longer exposure of the same blot showed a decrease in the pool of ubiquitinated SMA only when Hsp70 is co-expressed. To demonstrate direct interaction between Hsp70 and SMA, soluble fractions from metabolically labeled cells were immunoprecipitated with anti-kappa antibody and analyzed with reducing SDS-PAGE. In cells co-transfected with Hsp70 and SMA, Hsp70 was specifically co-immunoprecipitated with SMA. Over-expression of an irrelevant cytosolic protein, serum glucocorticoid inducible kinase, did not result in association with SMA. Endogenous Hsp70 was also associated with SMA, but was not dramatically enriched. This indicates that over-expression of Hsp70 decreased the cytosolic aggregation and aggresome formation and improved the targeting of SMA for degradation by the proteasome.

Taken together, these experiments show that the fate of misfolded, amyloidogenic LC was altered by increased interactions with Hsp70 family chaperones on either side of the ER membrane: more SMA was retained in the ER, less was aggregated and more of it remained in a soluble state, whether in the lumen of the ER or in the cytosol. Since the majority of SMA at steady state is in the 5 dislocated, cytosolic pool, BiP would be expected to have less of an effect than Hsp70 when the total cellular protein is analyzed and this is indeed what we observed.

The inventors also found that An Hsp70-binding peptide derived from the LC sequence inhibits SMA aggregation *in vivo*. To optimize delivery of the peptide to all cellular compartments, it was synthesized with the 11-mer sequence from the HIV TAT protein at the N-terminus (Gius et 10 al., 1999). This TAT peptide permits the transduction of denatured proteins across cell membranes rapidly and efficiently in an energy- and receptor-independent fashion. In addition to the test peptide, TAT-TISS, another TAT-fusion was employed as a specificity control. This peptide, TAT-PASS, contains four amino acid substitutions and does not inhibit fibril formation *in vitro*. SMA transfected 15 cells were incubated overnight in the presence of increasing concentrations of ALLN and 50  $\mu$ M of each peptide. In the range of 1-10  $\mu$ g/ml ALLN, there was a progressive increase in the amount of SMA found in the soluble fraction on a per cell basis. Inclusion of the TAT-TISS peptide dramatically reduced the amount of SMA recovered at all ALLN concentrations tested. In contrast, the TAT-PASS peptide had no effect. Incubation of the same blots with anti-raf antibody demonstrated that equal cell equivalents were loaded across the gel.

20 The inventors also determined the effect of different concentrations of peptide on SMA following treatment with 10  $\mu$ g/ml ALLN. The TAT-TISS peptide decreased the yield of SMA in the insoluble fractions much more than in the detergent soluble fractions. The magnitude of the decrease was from 4 to 10-fold (n=3), in a peptide concentration-dependent fashion, whereas the TAT-PASS peptide had only a marginal effect even at the highest concentration used. As observed 25 with co-expression of Hsp70, upon addition of the TAT-TISS peptide, the ubiquitinated forms of SMA were diminished. This indicated that they were being maintained in a soluble form long enough to be kept off the aggregation pathway and were degraded by the proteasome.

Lastly, the inventors determined that the decrease in steady state level of SMA in the presence of TAT-TISS peptide correlated with a decrease in the frequency of aggresome formation, by scoring

anti-kappa stained cells. Roughly 30% of untreated cells exhibited aggresomes and this number increased to about 65% upon addition of ALLN. Transduction of TAT-TISS decreased the number of aggresomes by more than half, to 25%, about the same as in untreated cells, whereas addition of TAT-PASS peptide had no significant effect. Hence, the large decrease in insoluble SMA observed  
5 in the presence of TAT-TISS peptide coincides with a drop in aggresome formation.

In summary, the inventors have found that peptides which mimic the structure of amyloid-forming proteins are suitable agents in inhibiting fibril formation. Insertion of the peptides into a particular groove typically occupied by an adjacent fibril unit interrupts fibril assembly and thus  
10 prevents fibril formation.

When amyloidogenic light chain (LC) fails to fold properly it is dislocated out of the endoplasmic rediculum to the cytosol where two linked coping mechanisms are present. While much of the expelled light chain is degraded by proteasomes, another fraction of the light chain aggregates. The inventors founrd that the introduction of a specific peptide into the cell inhibits aggregation and increases the efficiency of LC degradation.  
15

The presence of a non-releasing BiP mutant ( or high levels of wild type BiP) traps SMA molecules in the ER lumen that would otherwise be disloacted to the cytosol for aggregation.

Alternatively, once dislocated, interaction of SMA with cytosolic Hsp 70 improves the efficiency of aggregation. Over-expression of Hsp 70 decreased the insoluble and ubiquitin-tagged pools of SMA that accumulate in the presence of proteasome inhibitors. In the absence of proteasome inhibitors, however, the level of endogenous Hsp 70 was sufficient to support degradation of most SMA light chains. The inventors have identified a kinetic competition between degradation and aggregation: when there is sufficient Hsp 70 present to keep SMA soluble, more of it gets degraded, but if the level of Hsp 70 is inadequate, then more SMA aggregates. SMA is a type of proteasomal  
20 substrate whose degradation is improved by chaperon interactions.  
25

FIG. 4 depicts the inventor's competitive inhibition model. SMA fails to progress along a productive folding pathway and hence both of its domains remain in the reduced state *in vivo*. The presence of the highly unstable  $\kappa 4$  protein is detected by BiP, presumably during or soon after its translocation across the ER membrane. Binding to BiP prevents SMA aggregation in the lumen and

facilitates its dislocation back to the cytosol. Once there, binding to Hsp70 (or related chaperones) serves to maintain SMA in a degradation-competent state, so that it can be ubiquitinated and rapidly targeted to proteasomes. At the same time, Hsp70 inhibits the tendency of SMA to aggregate in the cytosol, thus regulating the balance between degradation and aggregation.

5 The inability to fold exposes (at least) the two major peptides in each of the two  $\beta$  sheets of the V domain that are good sites for binding of Hsp70 family chaperones. Continued exposure of these sites enables associations first with BiP (within the ER) and then with Hsp70 (in the cytosol). The FTLTISS peptide which is effective in reducing intracellular aggregation has the sequence of one of these two major sites, and importantly, the same features that are required for its anti-aggregation 10 activity are necessary for its Hsp70 binding activity.

15 The inventors envisage the peptide to interact with the same amino acids in the hydrophobic core of the V domain normally occupied in the folded molecule by the endogenous FTLTISS peptide. In this way, the peptide acts as a surrogate chaperone, inhibiting aggregation and promoting degradation. This provides a new avenue for treatment modalities using rationally designed peptides to suppress aggregation.

While the invention has been described through the embodiments disclosed herein, it should be noted that the embodiments are not intended to limit the scope of the following claims.

CLAIMS

The invention in which an exclusive right is asserted is claimed as follows:

1. A method for minimizing the aggregation tendencies of an amyloid forming protein,  
2. the method comprising:

3. a) identifying a first amino acid sequence of the protein that is replaced by a  
4. second amino acid sequence during physiological conditions; and  
5. b) preventing the replacement by juxtaposing a peptide to the first amino acid  
6. sequence.

1. 2. The method as recited in claim 1 wherein the method is conducted *in vivo*.

1. 2. 3. The method as recited in claim 1 wherein the protein is a human protein selected from  
the group consisting of human kappa-IV light chain variable domain and serine protease inhibitors.

1. 2. 4. The method as recited in claim 3 wherein the peptide has an amino acid sequence  
identical to an amino acid sequence in a region of the light chain variable domain.

1. 2. 5. The method as recited in claim 3 wherein the peptide is inserted between residue  
position numbers 60 and 83 of the protein.

1       6.     The method as recited in claim 3 wherein the peptide has the amino acid sequence

2                   Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub>

3     and wherein the subscripts denote the positions of the amino acids in the domain.

1       7.     The method as recited in claim 1 wherein the peptide is inserted when the protein is

2     partially unfolded.

1       8.     The method as recited in claim 1 wherein the peptide is identical in composition to a

2     portion of the protein that anchors a hairpin-shaped amino acid sequence to the protein.

1       9.     The method as recited in claim 1 wherein the protein is a greek key fold protein

2     selected from the group consisting of antibody constant domains, transthyretin, beta-2-microglobulin,  
3     serine protease inhibitors, and crystalline.

1       10.    The method as recited in claim 9 wherein the peptide is inserted at a hairpin anchorage

2     point in the greek key fold protein.

1       11.    The method as recited in claim 1 wherein the peptide is a target for an endoplasmic

2     reticulum chaperone.

1       12.    The method as recited in claim 1 wherein the peptide is an endoplasmic reticulum

2     chaperone selected from the group consisting of hsp70, hsc73 and BiP.

1       13.    The method as recited in claim 1 wherein the peptide is a synthetic peptide selected

2     from the group consisting of TDFTLTI, FTLTISS, FTLKISR, FTLEISR, and LTLKLSR.

1 14. A peptide for insertion in an intact human kappa-IV light chain variable domain, the  
2 peptide comprising the following amino acid sequence:

3 Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub>

4 wherein the subscript numbers are the residue location points in the domain.

1 15. A method for preventing amyloid formation in human kappa-IV light chain variable  
2 domain, the method comprising inserting the peptide Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub> into the  
3 domain, wherein the subscript numbers indicate the residue location on the domain.

16. The method as recited in claim 15 wherein the domain is partially unfolded at the time  
1 of insertion.

17. A method for preventing fibril assembly, the method comprising:  
a) identifying a region of a first aggregating protein moiety that normally interacts  
with a second protein moiety to form the assembly; and

18. The method as recited in claim 17 wherein the first and second aggregating proteins  
2 are immunoglobulin light chains.


1 19. The method as recited in claim 17 wherein the binding protein hybridizes with the  
2 region.

1        20. The method as recited in claim 17 wherein the binding protein is an amino acid  
2 sequence that is complementary to the amino acid sequence of the region

### ABSTRACT

A method for minimizing the aggregation tendencies of an amyloid forming protein is provided comprising identifying a portion of the protein that is critical to amyloid formation; and inserting a peptide at the portion. The invention also provides a peptide for insertion in an intact human kappa-IV light chain variable domain, the peptide comprising the following amino acid sequence Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub> wherein the subscript numbers are the residue location points in the domain. A method for preventing amyloid formation in human kappa-IV light chain variable domain is also provided, the method comprising inserting the peptide Phe<sub>71</sub>-Thr<sub>72</sub>-Leu<sub>73</sub>-Thr<sub>74</sub>-Ile<sub>75</sub>-Ser<sub>76</sub>-Ser<sub>77</sub> into the domain, wherein the subscript numbers indicate the residue location on the domain.


FIG 1



bioRxiv preprint doi: <https://doi.org/10.1101/2023.06.06.540323>; this version posted June 6, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [aCC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).

A

B

**A****B**

Sequence	Aggregation Inhibition
SGSGT <u>D</u> F <u>T</u> L <u>T</u> I <u>S</u> S <u>L</u> Q	+
TD <u>F</u> T <u>L</u> T <u>I</u> I	+
F <u>T</u> L <u>T</u> I <u>S</u> S	+
F <u>T</u> L <u>K</u> I <u>S</u> R	+
F <u>T</u> L <u>E</u> I <u>S</u> R	+ / -
<u>L</u> <u>T</u> L <u>K</u> <u>L</u> S <u>R</u>	+
F <u>T</u> L <u>P</u> I <u>S</u> R	-
A <u>T</u> L <u>K</u> I <u>S</u> R	-
F <u>T</u> A <u>K</u> I <u>S</u> R	-
F <u>T</u> L <u>K</u> A <u>S</u> R	-
<hr/>	
Scrambled: TRTFSKL	-

**FIG 2**




FIG 3




FIG 4